Welcome to Medications.com

Januvia News

Kindler's New Way - Forbes

... psoriasis and Crohn's disease; and a diabetes drug similar to Merck's (nyse: MRK - news - people ) blockbuster Januvia. Pain drugs are one focus. ...

http://www.forbes.com/business/20... | Posted: Wed Mar 05 15:09:00 -0500 2008

Pfizer gives megadeals the boot - The Star-Ledger - NJ.com

... that could treat rheumatoid arthritis and other inflammatory diseases; and a diabetes medicine that uses a mechanism similar to Merck's Januvia. ...

Posted: Thu Mar 06 00:51:25 -0500 2008

Pfizer gives megadeals the boot - The Star-Ledger - NJ.com

... that could treat rheumatoid arthritis and other inflammatory diseases; and a diabetes medicine that uses a mechanism similar to Merck's Januvia. ...

http://www.nj.com/business/ledger... | Posted: Thu Mar 06 00:51:25 -0500 2008

EU approves Novartis combo diabetes drug Eucreas - Pharma Times (subscription)

Now that Galvus and Eucreas are available in Europe, Novartis can now take on Merck & Co’s rival product Januvia (sitagliptin) and analysts believe that ...

http://www.pharmatimes.com/WorldN... | Posted: Mon Feb 25 05:53:08 -0500 2008

World’s First Approved DPP-4 Inhibitor for Type 2 Diabetes Now ... - Scoop.co.nz

JANUVIA is expected to be available to purchase on prescription from March. JANUVIA is the first in a new class of drugs known as dipeptidyl peptidase-4 ...

http://www.scoop.co.nz/stories/GE... | Posted: Wed Feb 27 21:37:52 -0500 2008

MNCs` diabetes drug patents worry experts - Business Standard

Globally marketed as Januvia, Merck’s Sitagliptin recorded $668 million in worldwide sales in 2007 and is projected to reach $2 billion by 2011. ...

http://www.business-standard.com/... | Posted: Wed Feb 27 13:42:41 -0500 2008

World’s First Approved DPP-4 Inhibitor for Type 2 Diabetes Now ... - Scoop.co.nz

all 5 news articles

Posted: Wed Feb 27 21:37:52 -0500 2008

EU approves Novartis combo diabetes drug Eucreas - Pharma Times (subscription)

Now that Galvus and Eucreas are available in Europe, Novartis can now take on Merck & Co’s rival product Januvia (sitagliptin) and analysts believe that ...

Posted: Mon Feb 25 05:53:08 -0500 2008

OSI Pharmaceuticals Inc. Q4 2007 Earnings Call Transcript - Seeking Alpha

Our DP-IV patent estate continues to be a very valuable asset to the organization and with Merck reporting a 2007 annualized exit run-rate for Januvia and ...

http://seekingalpha.com/article/6... | Posted: Thu Feb 21 22:01:42 -0500 2008

Type 2 diabetes driving epidemic - Pharmaceutical Business Review

... drugs like Merck's Januvia and Amylin/Lilly's Byetta are likely to be adopted by international guidelines and recommended treatment algorithms in the ...

http://www.pharmaceutical-busines... | Posted: Thu Feb 21 22:14:17 -0500 2008




© 2002-2007, Skylabs Inc.  |  About Us  |  Disclaimer/Terms of Use  |  Advertise  |  Contact Us  |  Site Map  |  Developed by: W3matter.com | Sleep Apnea